Immatics’ Series D Adds $46M for Phase III Renal Cancer Trial
LONDON – Immatics Biotechnologies GmbH has closed a €34 million (US$46.1 million) Series D financing, enabling it to complete Phase III development of lead cancer vaccine IMA901 in renal cancer and complete all preparations for filing with the FDA and the European Medicines Agency.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter